ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2018
Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 48 citations in OpenAlex.
- Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach.Progress in biomedical engineering (Bristol, England) · 2026Review
- Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In Vivo.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- PET-based tracking of CAR T cells and viral gene transfer using a cell surface reporter that binds to lanthanide complexes.Nature biomedical engineering · 2025Article
- IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Nuclear Nanomedicines: Utilization of Radiolabelling Strategies, Drug Formulation, Delivery, and Regulatory Aspects for Disease Management.Current radiopharmaceuticals · 2025Review
- Development of an antigen-based approach to noninvasively image CAR T cells in real time and as a predictive tool.Science advances · 2024Article
- Noninvasive longitudinal PET/CT imaging of CAR T cells using PSMA reporter gene.European journal of nuclear medicine and molecular imaging · 2024Article
- Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer.Current issues in molecular biology · 2023Review
- Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications.Theranostics · 2023Article
- Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy.Frontiers in medicine · 2023Review
- Pretargeting: A Path Forward for Radioimmunotherapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Review
- Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients.Journal for immunotherapy of cancer · 2022Review
- ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD.Blood advances · 2022Article
- Whole-Body Imaging to Assess Cell-Based Immunotherapy: Preclinical Studies with an Update on Clinical Translation.Molecular imaging and biology · 2022Review
- Development of a Radiotracer for PET Imaging of the SNAP Tag.ACS omega · 2022Article
- A multimodal imaging workflow for monitoring CAR T cell therapy against solid tumor from whole-body to single-cell level.Theranostics · 2022Article
- Highly aminated iron oxide nanoworms for simultaneous manufacturing and labeling of chimeric antigen receptor T cells.Journal of magnetism and magnetic materials · 2022Article
- PET/MRI Improves Management of Children with Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Review
- Imaging CAR T-cell kinetics in solid tumors: Translational implications.Molecular therapy oncolytics · 2021Article
- Metabolic radiolabeling and in vivo PET imaging of cytotoxic T lymphocytes to guide combination adoptive cell transfer cancer therapy.Journal of nanobiotechnology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
There remains an urgent need for the noninvasive tracking of transfused chimeric antigen receptor (CAR) T cells to determine their biodistribution, viability, expansion, and antitumor functionality. DOTA antibody reporter 1 (DAbR1) comprises a single-chain fragment of the antilanthanoid-DOTA antibody 2D12.5/G54C fused to the human CD4-transmembrane domain and binds irreversibly to lanthanoid (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.